Common cold virus could get work in gene therapy delivery; GSK secures microparticle supplies from Flamel Technologies

> Researchers at the Loyola University Stritch School of Medicine made findings about the common cold virus that could help develop versions of the virus as modes of transportation for gene therapies. Release

> Archimedes Pharma has released a nasal spray of fentanyl called Lazanda in the U.S. for breakthrough cancer pain. The FDA approved the product on June 30, making it the first U.S.-approved spray version of the potent painkiller. Item

> Apricus Biosciences has released details about a study of its NexACT technology as a "chemical enhancer" for delivering drugs through the cheek and into the skin. Article

> Encore Therapeutics has announced some upbeat preclinical data on its extended-release injectable formulation of the NSAID drug meloxicam, which was studied and compared with an oral version of the pain and inflammation medication. Release

> Flamel Technologies ($FLML) has hammered out a deal with GlaxoSmithKline ($GSK) to supply the London-based drug giant with Coreg CR microparticles and anticipates payments of €2.6 million. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.